相关实验视频

Updated: Jul 4, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

在接受勒沃多巴-卡比多巴肠凝治疗的患者中,优化口服恩塔卡的使用

Noriyuki Miyaue¹, Yuko Ito², Yuki Yamanishi²

¹Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan; Department of Neurology, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan.

Journal of the neurological sciences

|January 27, 2024

概括

在下午早些时候添加恩塔卡可能会改善帕金森氏症患者的下午症状,这些患者接受了勒沃多巴-卡比多巴肠凝 (LCIG). 这种辅助疗法有助于管理LCIG治疗期间的运动波动和临床恶化.

科学领域:

神经学神经学
药理学药理学是指药理学的学科.
运动障碍运动障碍

背景情况:

利沃多巴-卡比多巴肠凝 (LCIG) 有效地管理帕金森病的运动波动.
一些患者经历下午临床恶化,尽管LCIG治疗.
恩塔卡,一种COMT抑制剂,是一种潜在的辅助疗法,但最佳时间尚不清楚.

研究的目的:

为了研究口服恩塔卡的最佳时间.
在接受LCIG的帕金森病患者中改善下午的临床症状.

主要方法:

进行了药理动力学分析和症状评估.
测试了三种条件:没有恩塔卡,13:00的恩塔卡,15:00的恩塔卡.
招募了8名接受LCIG治疗的患者;7人完成了该研究.

主要成果:

13:00时的恩塔卡显著增加了勒沃多巴的血度,并降低了3-O-甲基多巴水平.
午后的"休息时间"在13:00和15:00服用恩塔卡时相比,没有恩塔卡的"休息时间"减少.
15:00的恩塔卡也影响了勒沃多巴和3-O-甲基多巴水平,尽管没有显著的影响.

结论:

在接受LCIG治疗的帕金森病患者中,在下午早些时候服用口服恩塔卡可能会改善下午症状.
恩塔卡作为管理LCIG相关下午症状恶化的辅助疗法具有前景.
对最佳剂量和时间策略的进一步研究是有必要的.

关键词:

3O 甲基多巴.恩塔卡胺 (Entacapone) 是一种莱沃多巴的药理动力学利沃多巴卡比多巴肠凝是一种肠凝.帕金森病是帕金森病的一种.

更多相关视频

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Published on: July 30, 2020

相关概念视频

Routes of Drug Administration: Enteral

Routes of Drug Administration: Enteral

Medications can be administered through the enteral route using liquids, capsules, or tablets.
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...

Drug Delivery: Enteral Route

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...